Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxytocin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Shalvata Mental Health Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxytocin is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
March 27, 2024
Lead Product(s) : Oxytocin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Shalvata Mental Health Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brizo
Therapeutic Area : Urology
Study Phase : Undisclosed
Recipient : Se-cure Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brizo is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Hyperplasia.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 07, 2022
Lead Product(s) : Brizo
Therapeutic Area : Urology
Highest Development Status : Undisclosed
Recipient : Se-cure Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amoxicillin Trihydrate
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Penicillin Allergy in Shfayim Clinic
Details : Amoxicillin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Penicillin Hypersensitivity.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 17, 2018
Lead Product(s) : Amoxicillin Trihydrate
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Aboca
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children.
Details : This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Cough.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 24, 2013
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Aboca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : HaEmek Medical Center, Israel
Deal Size : Inapplicable
Deal Type : Inapplicable
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
Details : Capecitabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2012
Lead Product(s) : Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : HaEmek Medical Center, Israel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis
Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 19, 2011
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Erlotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Erlotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2010
Lead Product(s) : Erlotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RoActemra (Tocilizumab) is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : RoActemra
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 23, 2010
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vitamin D
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Meir Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI)
Details : Vitamin D is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Acute Coronary Syndrome.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 04, 2010
Lead Product(s) : Vitamin D
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Meir Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Femarelle
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Recipient : Se-cure Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A Double-Blind Study to Evaluate the Effect of Femarelle® on Menopausal on Vasomotor Symptoms
Details : Femarelle is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 05, 2010
Lead Product(s) : Femarelle
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Recipient : Se-cure Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
